The pathogen-free pigs of the Xenotransplantation Research Center that will supply cells for transplants.
A shortage of organs for transplantation—including kidneys and hearts—means that many patients die while still on waiting lists.
in email correspondence with Futurism.
IUSM Assistant Professor of Surgery Dr.
But decades of scientific setbacks have kept clinical trials of that approach, called xenotransplantation, on the horizon.
Boston-based eGenesis recently received $38 million in Series A financing to develop a safer xenotransplant.
1 Address correspondence to: Mr.
a biotechnology company focused on utilizing genome editing technology to make xenotransplantation a routine and lifesaving medical procedure, today announced that it raised a $38 million Series A fin.
First Pigs without Active Porcine Endogenous Retrovirus (PERV) Produced Using CRISPR-Cas9 Genome Editing Technology – a Landmark Advance for Xenotransplantation eGenesis, a biotechnology company focus.
Using gene-editing, researchers have modified such organs to prevent rejection, and research with primates shows the modified pig organs are well-tolerated.